´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06±³À°ÀÏÀÚ : 2022-11-06
±³À°Àå¼Ò : ÄÚ¿¢½º ³²ÂÊ4Ãþ ÄÁÆÛ·±½º·ë
±³À°ÁÖÁ¦ :
(¿ÀÇÁ¶óÀÎ) ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÁöÀºÁ¤
¿¬¶ôó : 02-512-5915
À̸ÞÀÏ :
gyncancer@gyncancer.or.kr ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 5¸¸¿ø, Àü°øÀÇ3¸¸¿ø, ¿¬±¸¿ø/°£È£»ç2¸¸¿ø, ÁÂÀå/¿¬ÀÚ/Åä·ÐÀÚ/¸¸65¼¼ÀÌ»ó ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-06 401È£ 09:00~09:10 ºÎÀÎÁ¾¾çÀÇÇлó, JGO Best Reviewer ½Ã»ó½Ä ()
±âŸ 11-06 401È£ 09:10~09:15 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ¹ßÇ¥ ()
±âŸ 11-06 401È£ 09:15~09:20 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ»ó ¼ö»óÀÚ ¹ßÇ¥ ()
±³À°½Ã°£ 11-06 401È£ 09:20~09:35 Ovarian cancer ³²¼ÒÇö(¿ï»êÀÇ´ë)
Åä·Ð 11-06 401È£ 09:35~09:40 Designated discussion ÀÌÀºÁö(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 09:40~09:55 Cervical cancer and uterine cancer ³ëÁØÈ£(¼º±Õ°üÀÇ´ë)
Åä·Ð 11-06 401È£ 09:55~10:00 Designated discussion Àü¼·(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 10:00~10:15 Risk classification of endometrial cancer ¹Ú¼öÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 10:15~10:30 BRCA and HRD in high-grade ovarian cancer ³²ÀºÁö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 10:30~10:45 PD-L1, TMB, MMR status, and beyond for immunotherapy ÃÖÀ±Áø(°¡Å縯ÀÇ´ë)
Åä·Ð 11-06 401È£ 10:45~11:00 Designated discussion ±è¹Ì°æ(ÀÌÈÀÇ´ë)
ÈÞ½Ä 11-06 401È£ 11:00~11:20 Coffee Break ()
±³À°½Ã°£ 11-06 401È£ 11:20~11:35 Will the importance of complete cytoreduction continue or shrink? ±èÅÂÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 11:35~11:50 HIPEC or not, that is the question ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-06 401È£ 11:50~12:05 Are you ready for relapse after PARP inhibitors? ¹ÚÁ¤¿(¿ï»êÀÇ´ë)
Åä·Ð 11-06 401È£ 12:05~12:20 Designated discussion Á¤´ëÈÆ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 12:20~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer ÃÖöÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 12:35~12:50 Long-term results of PARPi as maintenance in front-line Antonio González Martín(Clínica Universidad de Navarra)
½Ä»ç 11-06 401È£ 12:50~13:40 Lunch ()
±³À°½Ã°£ 11-06 401È£ 13:40~13:55 Less radical surgery in early-stage cervical cancer ¹èÀ縸(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 13:55~14:10 Quality indicators of the radical surgery °øÅ¿í(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 14:10~14:25 CCRT: current standard & future perspective ±è¿ë¹è(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
Åä·Ð 11-06 401È£ 14:25~14:40 Designated discussion ³ëÁÖ¿ø(Â÷ÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 14:40~14:55 Fertility-preservation in gynecologic cancers ÀÌ»óÈÆ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 14:55~15:10 How to optimize elderly patients for cancer treatments? ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 15:10~15:25 Management of immunotherapy and targeted therapies-induced toxicities ÀåűÔ(°è¸íÀÇ´ë)
Åä·Ð 11-06 401È£ 15:25~15:40 Designated discussion ¹Ú¼ºÈ£(ÇѸ²ÀÇ´ë)
ÈÞ½Ä 11-06 401È£ 15:40~16:00 Coffee Break ()
±³À°½Ã°£ 11-06 401È£ 16:00~16:15 Uterine sarcoma ¼Ò°æ¾Æ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 16:15~16:30 Ovarian clear cell cancer ¼µ¿¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-06 401È£ 16:30~16:45 Ovarian low grade serous cancer È«´ë±â(°æºÏÀÇ´ë)
Åä·Ð 11-06 401È£ 16:45~17:00 Designated discussion ±Çº´¼ö(°æÈñÀÇ´ë)
±³À°½Ã°£ 11-06 403È£ 13:40~13:55 Assessment of quality of cancer patients Á¶ÁÖÈñ(¼º±Õ°ü´ë À¶ÇÕÀÇ°úÇпø)
±³À°½Ã°£ 11-06 403È£ 13:55~14:10 Tailored surgery for cervical cancer ±¸À¯Áø(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 11-06 403È£ 14:10~14:25 Guidelines and issues for ovarian cancer treatment ±è»óÀÏ(°¡Å縯ÀÇ´ë)
Åä·Ð 11-06 403È£ 14:25~14:35 Discussion ()
±³À°½Ã°£ 11-06 403È£ 14:35~14:50 ERAS & perioperative management ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-06 403È£ 14:50~15:05 Issue of nursing problem during the acute survival period ±èÁÖÇö(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11-06 403È£ 15:05~15:20 Clinical trial and research ethics related to gynecologic oncology ±è¼ö(¿¬¼¼´ë °£È£´ëÇÐ)
Åä·Ð 11-06 403È£ 15:20~15:30 Discussion ()